Cookie policy: This site uses cookies (small files stored on your computer) to simplify and improve your experience of this website. Cookies are small text files stored on the device you are using to access this website. For more information please take a look at our terms and conditions. Some parts of the site may not work properly if you choose not to accept cookies.

Join

Subscribe or Register

Existing user? Login

Insight

Illustration of over-the-counter products

Why the resurgence of POM-to-P reclassifications in the UK is a good thingSubscription

9 MAY 2017By

After a dwindle in the number of reclassifications of prescription-only to pharmacy medicines in the UK, things are starting to look up, writes Natalie Gauld.

Montage of researchers and a the hiv virus

What healthcare professionals can do to help limit HIV resistanceSubscription

3 APR 2017By

Limiting HIV resistance must not be neglected in an era where we continue to see breakthroughs in treatment for the infection once labelled a death sentence.

Illustration of a heart inside a pill bottle

Cholesterol-lowering statin therapy for healthy people is not as simple as 'yes' or 'no'Subscription

7 MAR 2017By

Recent reports of large trials extolling the virtues of statins have led many to believe that low-risk patients should take them, but an examination of the evidence provides food for thought.

Illustration of fractured bones and drugs

Why some patients are reluctant to take osteoporosis drugsSubscription

8 FEB 2017By

There are a number of factors that contribute to patients’ fear and reluctance to take osteoporosis drugs, leaving them at increased risk of fractures.

Identical vials held by gloved hands

Why biosimilars should be interchangeable with biologicsSubscription

9 JAN 2017By

Research suggests no substantive outcome differences between the use of originator biologics and their biosimilar counterparts Source: Shutterstock.com

Newsletter Sign-up

Want to keep up with the latest news, comment and CPD articles in pharmacy and science? Subscribe to our free alerts.